NJBIZ, New Jersey’s leading business journal, provides 24/7 business news coverage and events honoring top business professionals.

Barr Pharmaceuticals Inc. raised its buyout offer Friday for Croatian generic drug maker Pliva d.d. to $2.3 billion, topping an improved offer from Iceland’s Actavis Group HF. Barr said it would pay ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Actavis on Monday appeared to concede defeat in the takeover battle for Pliva, the Croatian drugs manufacturer.

On April 28, the US Food and Drug Administration's Center for Drug Evaluation and Research (Rockville, MD) issued a Warning Letter to Pliva Hrvatska d.o.o., a subsidiary of Pliva d.d. (Zagreb, Croatia ...

We’ll send you a myFT Daily Digest email rounding up the latest Barr Pharms news every morning. Size is not everything – unless you are one of the players in the global generic drugs industry. Barr ...

Barr Pharmaceuticals stepped up the pressure to buy Croatian generics company Pliva yesterday after filing its intentions formally with global regulators, including the US Federal Trade Commission and ...

Pliva?s new Oral Solid Forms Facility will increase Pliva's production capacities for tablets and capsules. Pliva's new oral solid forms facility at its production site in Zagreb will increase Pliva's ...

Croatia’s Pliva is to boost its generics capabilities with the purchase of a Spanish generics unit from Novartis’ Sandoz. The subsidiary – Uso Racional – has been snapped up for 21.5 million euros ...

SAN FRANCISCO (MarketWatch) -- Barr Pharmaceuticals Inc.'s $2.3 billion cash takeover offer for Pliva DD on Wednesday received the backing of the Croatian generic drugmaker's supervisory board. Based ...

Pliva, a Zagreb, Croatia-based drug firm, expects to complete its exit from the proprietary drug business with an agreement to sell an R&D unit to GlaxoSmithKline. GSK will pay an up-front fee of $35 ...

Ōmura S . Macrolide antibiotics. Chemistry, biology and practice, Second Edition, Academic Press Inc., San Diego, London ( 2002). Kirst HA . Structural Modification of Macrolide Antibiotics. Recent ...

NEW YORK (CBS.MW)-- Shares of Indevus Pharmaceuticals climbed 7.3 percent to $6.49 after announcing a promotion and licensing agreement with Pliva, via its subsidiary Odyssey Pharmaceuticals, to ...